MÖMesut Melih Özercan

Mesut Melih Özercan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mesut Melih Özercan has a total of 101 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A RARE COMPLICATION OF VATS: ACQUIRED INTERCOSTAL LUNG HERNIATION

    by Serkan Uysal, Mesut Melih Özercan, Yiğit Yılmaz, Ulaş Kumbasar

    Lung herniation is a rare condition defined as the protrusion of lung parenchyma through a defect in the thoracic wall. It is usually caused by trauma or iatrogenic factors. A 57-year-old male patient underwent thoracoscopic surgery for a solitary pulmonary nodule in the right upper lobe in 2017. He presented in late 2019 with a worsening cough and a painful bulging mass on the anterior chest wall. Computed tomography (CT) confirmed the diagnosis of lung herniation. Surgical repair was performed using a prosthetic mesh. The patient was discharged on the second post-operative day with complete resolution of symptoms. We present this case to highlight pulmonary herniation as a rare complication following Video-Assisted Thoracoscopic Surgery (VATS) and discuss it in light of recent literature.

  • AKCİĞER KARSİNOİD TÜMÖRLERİNDE CERRAHİ TEDAVİ VE PROGNOSTİK FAKTÖRLER:TEK MERKEZ DENEYİMİ

    by Serkan Uysal, Ulaş Kumbasar, Burcu Ancın, Mesut Melih Özercan, Yiğit Yılmaz, Erkan Dikmen, Rıza Doğan

    Amaç: Akciğer karsinoid tümörleri, düşük malignite potansiyeline sahip olmasına rağmen cerrahi rezeksiyonun altın standart olduğu nadir nöroendokrin tümörlerdir. Bu çalışmanın amacı, kliniğimizde opere edilen akciğer karsinoid tümörlü hastaların klinikopatolojik özelliklerini, başvuru semptomlarını, uygulanan cerrahi yöntemleri ve uzun dönem sağkalım sonuçlarını histopatolojik alt tipler eşliğinde değerlendirmektir. Gereç ve Yöntemler: Kliniğimizde akciğer karsinoid tümörü tanısı ile cerrahi tedavi uygulanan 41 hastanın verileri retrospektif olarak incelendi. Hastalar histopatolojik olarak tipik ve atipik karsinoid olmak üzere iki gruba ayrıldı. Demografik veriler, başvuru şikâyetleri, tümör özellikleri, cerrahi prosedürler ve sağkalım durumları analiz edildi. Sağkalım analizleri Kaplan-Meier yöntemi ile, gruplar arası karşılaştırmalar Log-rank ve Mann-Whitney U testleri ile yapıldı.Bulgular: Çalışmaya dahil edilen 41 hastanın (26 Kadın, 15 Erkek) yaş ortalaması 49,0±12,7 yıldı. Başvuru anında hastaların %43,9’unun (n=18) asemptomatik olduğu, semptomatik hastalarda ise en sık öksürük (%22) ve nefes darlığı (%14,6) görüldüğü saptandı. Histopatolojik incelemede 32 (%78) hastada tipik, 9 (%22) hastada atipik karsinoid mevcuttu. En sık uygulanan cerrahi yöntem lobektomi (%58,5) iken, parankim koruyucu cerrahi oranı %26,8 idi. Ortalama takip süresi 133,8±54,5 aydı. Beş yıllık genel sağkalım oranı tipik karsinoid grubunda %93,8, atipik karsinoid grubunda %88,9 olarak bulundu. İki grup arasında sağkalım açısından istatistiksel olarak anlamlı fark saptanmadı (p=0,336).Sonuç: Akciğer karsinoid tümörlerde cerrahi rezeksiyon, düşük komplikasyon ve yüksek sağkalım oranları ile güvenli bir tedavi seçeneğidir. Hastaların önemli bir kısmının asemptomatik olması, insidental tanıların arttığını göstermektedir. Erken evrede yakalanan ve tam rezeksiyon uygulanan atipik karsinoidlerde de tipik varyantlar kadar yüz güldürücü uzun dönem sonuçları elde edilebilir.

  • Clinical characteristics of four children with azygos lobe: A Case Report

    by Yaşar Kandur, Mesut Melih Özercan, Nesimi Günal, Ayşegül Alpcan, Dilek Azkur

  • Open Access

    Evaluation of prognostic value of vascular endothelial growth factor and endocan in non-small cell lung cancer

    by Mesut Meli̇h Özercan, Burcu Ancin, Yi̇ğİt Yilmaz, Ahmet Müderri̇sOğlu, Serkan Uysal, Ulaş Kumbasar, Zeynep Saribaş, Erkan Di̇kMen, Riza Doğan

    Background/aim: No reliable, easily measurable biomarker currently exists for the screening or prognosis of lung cancer. The present study evaluates the potential utility of vascular endothelial growth factor (VEGF) and endocan, which can be readily measured in blood samples, as biomarkers for screening and prognostic assessment in lung cancer. Materials and methods: Included in the study were 38 patients with early-stage non-small cell lung cancer (NSCLC) and 29 controls. All patients underwent surgical intervention and were monitored for 1 month postoperatively. Serum VEGF and endocan levels were measured preoperatively and postoperatively. Clinical characteristics, laboratory data, and histopathological findings were recorded for all participants. Results: The preoperative VEGF levels of the patients were significantly higher than those of the controls (p = 0.001), while postoperative VEGF levels decreased significantly following surgery (p < 0.001). The endocan levels of the patients and controls were similar preoperatively. Additionally, endocan levels were significantly increased after the surgery in the patient group (p < 0.001). A comparison of VEGF and endocan levels according to TNM staging and tumor histopathology revealed no significant differences. Conclusion: VEGF can serve as a potential biomarker for screening and prognostic assessment in early-stage NSCLC. In contrast, endocan did not demonstrate utility for such clinical purposes. VEGF may also be considered for the evaluation of treatment efficacy following surgical intervention.


  • Relationship between HE4 levels and metabolic parameters in PET of non-small cell lung cancer patients

    by Yiğit Yilmaz, Mesut Melih Özercan, Burcu Ancin, Zeliha Günnur Dikmen, Meltem Cağlar Tuncali, Murat Tuncel, Serkan Uysal, Ulaş Kumbasar, Erkan Dikmen, Rıza Doğan

    To investigate the relationship between serum human epididymis protein 4 (HE4) levels and metabolic parameters of positron emission tomography (PET) imaging in patients with lung cancer. Sixty non-small cell lung cancer (NSCLC) patients were included in this prospective study. Demographic information, smoking status, comorbid pathologies, preoperative HE4 levels, PET imaging metabolic parameters, disease stage and histopathology were recorded. Significant positive correlations between serum HE4 levels and all the metabolic parameters were observed (p < 0.05). In univariate regression analyses, it was observed that high serum HE4 levels could indicate tumor be squamous cell carcinoma (SCC) (p = 0.029), advanced T stage (p = 0.041), and have high maximum standart uptake value (SUVmax) (p = 0.017). Serum HE4 levels can be used as a biomarker to predict tumor burden and metabolic activity for NSCLC patients. Although sufficient per power analysis, this study may have benefited from further expansion, and by patient heterogeneity in TNM stage and tumor histology, potentially affecting the assessment of parameter relationships.

  • Open Access

    Onkolojik Cerrahi

    by Güntuğ Batıhan, Funda Cansun, Ezin Cem Yeni, Arkın Acar, Mehmet Çetin, Mesut Melih Özercan, Baris Gülmez, İsMail Aytaç, Yusuf Arslanhan, Ozan Tüysüz, et al.

    Erken Evre Küçük Hücreli Dışı Akciğer Kanserinde Minimal İnvaziv Cerrahi Seçenekleri Güntuğ BATIHAN Funda CANSUN Küçük Hücreli Akciğer Kanserinde Cerrahi Tedavi Ezin Cem YENİ Malign Plevral Mezotelyomada Cerrahi Tedavi Seçenekleri Arkın ACAR Akciğer Nöroendokrin Tümörlerinin Cerrahi Tedavisi Mehmet ÇETİN Timoma ve Timik Karsinomlarda Cerrahi Tedavi Mesut Melih ÖZERCAN Trakeal Tümörlerde Cerrahi Yaklaşım Barış GÜLMEZ Oral Kavite ve Orofarinks Tümörlerinin Cerrahi Tedavisi İsmail AYTAÇ Yusuf ARSLANHAN Nazofarenks Tümörlerinde Cerrahi Tedavi Ozan TÜYSÜZ Larenks Kanserlerinde Cerrahi Tedavi İsmail AYTAÇ Berkay GÜZEL Baş Boyun Kanserlerinde Rekonstrüktif Cerrahi Yaklaşımlar Ceyhun CENGİZ Tükrük Bezi Tümörlerinde Cerrahi Yaklaşımlar Sercan ÇIKRIKCI Secaattin GÜLŞEN Nazal Kavite ve Paranazal Sinüs Tümörlerinde Cerrahi Yaklaşımlar Fatih Mehmet HANEGE Tiroid Kanserlerinde Cerrahi Tedavi Serdal ÇELİK Paratiroid Karsinomlarında Cerrahi Tedavi Elvan ONAN Malign Göz Kapağı Tümörlerine Yaklaşım Neşe ARSLAN Şule BARMAN KAKİL Retina ve Koroidin Vasküler Tümörleri Özlem BURSALI Orbita Tümörlerine Yaklaşım Emin Serbülent GÜÇLÜ Primeri Bilinmeyen Boyun Tümör Metastazlarında Cerrahi Tedavi Elvan ONAN Erken Evre Meme Kanserinde Cerrahi Yaklaşım Recayi ÇAPOĞLU Meme Koruyucu Cerrahi Endikasyonları ve Teknikleri Mesut YUR Onkoplastik Meme Koruyucu Cerrahi Teknikleri Cüneyt AKYÜZ Aksiller Sentinel Lenf Nodu Biyopsisi Ertuğrul Gazi ALKURT Lokal İleri Evre Meme Kanserinde Aksilla Yönetimi Nurhan Haluk BELEN Aksiller Tersine Haritalama (ARM: Axillary Reverse Mapping) Hasan UZER Meme Kanserinde Neoadjuvan Tedavi Sonrası Cerrahi Yaklaşım Ali DURAN Uğur MENGENECİ Meme Kanserinde Lokal Nüks Durumunda Cerrahi Tedavi Zülfü BAYHAN Metastatik Meme Kanserinde Primer Tümör Cerrahisi Emin TÜRK Onkolojik Meme Cerrahisi Sonrası Meme Rekonstrüksiyon Yöntemleri Mehmet RENÇBER Mehmet Tolga KAFADAR Meme Kanserlerinde Robotik Cerrahi Uygulamaları Yaşar ÇÖPELCİ Umut Rıza GÜNDÜZ Meme Kanserinde Profilaktik Mastektomi Mehmet PATMANO Erken Evre Özofagus Kanserinde Cerrahi Tedavi Seçenekleri İsa Caner AYDIN Yasin TOSUN Erken Evre Özofagus Kanserlerinde Minimal İnvazif Cerrahi Tedaviler Sacit Altuğ KESİKLİ Lokal İleri Evre Özefagus Kanserinde Cerrahi Yaklaşımlar Azmi LALE Erken Evre Mide Kanserinde Cerrahi Tedavi Seçenekleri Elif TUNCAY Erken Evre Mide Kanserinde Minimal İnvaziv Cerrahi Tedavi Mehmet ÖZER Mide Kanserinde Lenf Nodu Diseksiyonunun Önemi ve Teknikleri Onur KILIÇ Lokal İleri Mide Kanserinde Cerrahi Tedavi Seçenekleri Aziz BULUT Mehmet UÇAR İzole Peritoneal Metastazlı Mide Kanserinde Sitoredüktif Cerrahi ve Hipertermik İntraperitoneal Kemoterapinin Yeri Mehmet ASLAN Metastatik Mide Kanserinde Palyatif Cerrahi Tedavi Osman BARDAKÇI Mide Kanseri Cerrahisi Komplikasyonları Üsküdar Berkay ÇARALAN İnce Barsak Malign Tümörlerinde Cerrahi Tedavi Serkan CEYLAN Laparoskopik İnce Barsak Cerrahisi Murat SEVMİŞ Erken Evre Kolon Kanserinde Cerrahi Tedavi Salih DEMİRELLİ Oligometastatik Kolon Kanserinde Primere Cerrahi Yaklaşım Mete YAZI Gökçe ACUN Oligometastatik Kolon Kanserlerinde Karaciğer Metastazlarına Genel Yaklaşım Ö. Bilgehan POYRAZOĞLU Kolon Kanserinde Stoma Yönetimi Emin TÜRK Rektal Kanserlerde Cerrahi Tedavi Seçenekleri Ali Erkan UÇAR Rektal Kanserlerde Minimal İnvaziv Cerrahi Tedaviler Erkan KARACAN Anal Kanserlerde Cerrahi Tedavi Seçenekleri Alirıza ERDOĞAN Hepatoselüler Karsinom Tedavisinde Cerrahi Yöntemler Hüseyin Fahri MARTLI Potansiyel Rezektable Hepatoselüler Karsinomlarda Cerrahi Yaklaşım Seda ARZUMAN BAŞTÜRK Hepatosellüler Kanser Tedavisinde Karaciğer Transplantasyonu Seyyit Muhsin SARIKAYA Karaciğer Tümörlerinde İntraarteriyel Tedaviler Sinan KARATOPRAK Karaciğer Tümörlerinde Lokal Ablatif Tedaviler Nurullah DAĞ İntrahepatık Kolanjıoseluler Karsınomda Cerrahi Tedavi Yöntemleri Ramazan TOPCU Kanser Cerrahisinde Tromboemboli ve Profilaksisi Ceyda ASLAN Malign Safra Yolu Obstruksiyonunda Palyatif Cerrahi Yaklaşımlar Doğukan DURAK Pankreas Başı Tümörlerinde Cerrahi Tedavi Yavuz Selim KAHRAMAN Pankreas Gövde ve Kuyruk Tümörlerinde Cerrahi Tedavi Halil İbrahim TAŞCI Pankreas Kanserlerinde Palyatif Cerrahi Yaklaşımlar Sümeyra GÜLER Harun KARABACAK Erken ve Lokal İleri Evre Böbrek Kanserlerinde Cerrahi Tedavi Ahmet GÜZEL Metastatik Böbrek Tümörlerinde Cerrahi Tedavi Sefa Alperen ÖZTÜRK Ürotelyal Kanserlerde Cerrahi Tedavi Seçenekleri Şeref COŞER Mesane Kanserinde Cerrahi Tedavi Ferec AFENDIYEV Erken ve Lokal İleri Evre Prostat Kanserinde Cerrahi Tedavi Murat KESKE Gökhan SÖNMEZ Testis Tümörlerinde Cerrahi Tedavi Ender Cem BULUT Penil Tümörlerde Cerrahi Tedavi İrfan Şafak BARLAS Erken ve Lokal İleri Evre Serviks Kanserinde Cerrahi Tedavi Pınar ERDOĞAN Erken ve Lokal İleri Evre Vajen Kanserinde Cerrahi Tedavi Filiz...

  • Open Access

    The correlation of serum sPD-1 and sPD-L1 levels with clinical, pathological characteristics and lymph node metastasis in nonsmall cell lung cancer patients

    by Burcu Ancin, Mesut Meli̇h Özercan, Yi̇ğİt Yilmaz, Serkan Uysal, Ulaş Kumbasar, Zeynep Saribaş, Erkan Di̇kMen, Riza Doğan, Meti̇n Demi̇rCi̇n

    Background/aim: Significant advances have been achieved in immunotherapy for the treatment of lung cancer. It is known that tumor cells and cells in the tumor microenvironment express high amounts of programmed cell death ligand 1 (PD-L1). These PD-L1s interact with programmed cell death protein 1 (PD-1), causing immunosuppression. The aim of our study is to examine the correlation between the serum sPD-1 and sPD-L1 levels and clinicopathological characteristics in patients with nonsmall cell lung cancer. We also compared our results with the healthy population (control group). Materials and methods: Thirthy-seven nonsmall cell lung cancer (NSCLC) patients who were operated in our clinic were included in our study. The control group included fifteen healthy patients. The sPD-1 and sPD-L1 levels were measured in serum samples by using the ELISA method. Results: The preoperative sPD-1 and sPD-L1 levels were significantly higher in the study group compared to the control group (44.12 ± 22.25 pg/mL vs. 18.54 ± 6.56 pg/mL; p = 0.001 and 26.15 ± 18.03 pg/mL vs. 10.29 ± 3.08 pg/mL; p = 0.001, respectively). There was a statistically significant decline in serum sPD-1 and sPD-L1 levels at the preoperative and postoperative 1st, 7th, and 30th days following surgical resection (44.12 ± 22.25 pg/mL, 37.86 ± 18.02 pg/mL, 36.33 ± 18.36 pg/mL, 34.14 ± 13.71 pg/mL; p = 0.007 and 26.15 ± 18.03 pg/mL, 20.60 ± 15.50 pg/mL, 18.31 ± 14.04 pg/mL, 13.64 ± 10.60 pg/mL; p = 0.001, respectively).There was a positive correlation between the preoperative and postoperative 30th day serum sPD-1 levels and the tumor size (p = 0.031, r = 0.352; p = 0.024, r = 0.371; respectively). We also found a positive correlation between the preoperative and postoperative 30th day serum sPD-L1 levels and pleural invasion (p = 0.001, p = 0.001; respectively), and the N category (p = 0.015, p = 0.013; respectively). Conclusion: We think that sPD-1 and sPD-L1 levels may be used as a potential biomarker for lung cancer screening, prediction of the stage, and besides to detect recurrences and/or metastases following resection in NSCLC following validation with multicenter and larger-scale prospective trials.


  • Comparison of Early Postoperative Outcomes of Patients Undergoing Robot-Assisted and Transsternal Thymectomy

    by Burcu Ancin, Mesut Melih Ozercan, Yigit Yilmaz, Serkan Uysal, Ulas Kumbasar, Erkan Dikmen, Mustafa Yilmaz, Riza Dogan

    Objective: Robot-assisted thoracoscopic surgery (RATS) is a minimally invasive technique that has been used in thymectomy operations in recent years. Minimally invasive surgical techniques offer less postoperative pain, a shorter length of hospital stay, and faster recovery compared to conventional surgical techniques. In our study, we aimed to compare the outcomes of robotic and transsternal thymectomies by analyzing the operative and postoperative data of these two approaches. Methods: Twelve robotic thymectomy patients and 16 transsternal thymectomy patients who were operated on in our clinic in 2018 were included in the study. Results: There was no significant difference between the two groups in terms of operative time (p=0.231). The median chest tube duration was 1.5 [range, 1-2] days in robotic thymectomy and 2.5 [range, 1-3.75] days in transsternal thymectomy. However, there was no statistically significant difference between the two groups (p=0.082). The amount of chest tube drainage was significantly lower in the robotic thymectomy group (p=0.006). The length of hospital stay was also significantly shorter in robotic thymectomy patients (p<0.001). Conclusion: The amount of chest tube drainage was lower and the length of hospital stay was shorter in the robotic surgery compared to the transsternal approach. There was no significant difference between the two techniques in terms of operative time. Within today's minimally invasive surgical techniques, robotic thymectomy can be considered a practical, comfortable, and safe technique with better early postoperative outcomes. Keywords: Robot-Assisted Thymectomy, Thymectomy, Transsternal Thymectomy